Anticoagulation for Aortic Bioprosthesis (ANTIPRO)
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the clinical and hemodynamic outcome in patients after aortic valve
replacement. Half of the patients will receive warfarin + aspirin and the other half will
receive only aspirin. The investigators will focus mainly on early bioprosthesis
degeneration.